Cardiol Therapeutics Inc.
TSX:CRDL.TODrug Manufacturers - Specialty & Generic
+$0.00 today
- Market cap
- $164.10M
- Beta
- 0.48
- P/E (TTM)
- -4.5
- EPS (TTM)
- -$0.33
Volume 0.08M
Average 0.12M
CRDL.TO Selling, General & Admin
Overhead costs of running the business, including sales, marketing, management, and administrative staff.
Cardiol Therapeutics Inc.TSX: CRDL.TO
Selling, General & Admin · Q1 FY2026 · quarter ended Mar 2026
Selling, general & admin growth accelerates
Q1 FY2026 selling, general & admin of CA$4.73M rose 1.8% year over year, ahead of the -21.3% change in trailing-twelve-month selling, general & admin. Sequentially, it fell 10.1% from the prior quarter. Over 3 fiscal years it compounded at -3.4% a year.
Context
- Selling, general & admin increased in 1 of the last 3 fiscal years.
What to watch
Whether selling, general & admin reaches the consensus estimate from 4 analysts of CA$107.61M (+432.8%) for the fiscal year ending Dec 2026, a step up from the -22.0% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- CA$4.73M-10.1% QoQ
- Last fiscal yearDec 2025
- CA$20.2M-22.0% YoY
- LTMMar 2026
- CA$20.28M-21.3% YoY
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Selling, General & Admin history
CAD · from the income statement
- Latest · FY2025
- 20.2M CAD
- Year-over-year change
- -22.0%
- 4-year CAGR
- -7.7%
| Period | Period end | Selling, General & Admin | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 20.2M | -22.0% |
| FY2024 | 2024-12-31 | 25.89M | +66.4% |
| FY2023 | 2023-12-31 | 15.56M | -30.4% |
| FY2022 | 2022-12-31 | 22.37M | -19.7% |
| FY2021 | 2021-12-31 | 27.87M | — |
Selling, General & Admin vs competitors
How CRDL.TO compares with its peers on the latest reported figures
- Peers report in different currencies, so selling, general & admin is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of -21.3% is the lowest of 2, against a peer median of -15.0%.
- Over three fiscal years its annual growth of -3.4% compares with a peer median of -2.1%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $21.73M USD | -15.0% | -14.8% | 39.0% | |
| LTM Mar 2026 | CA$20.28M CAD | -21.3% | -3.4% | — | |
MSCL.TOSatellos Bioscience Inc. | LTM Mar 2026 | $7.71M USD | — | +10.7% | — |
| Peer median (excluding CRDL.TO) | — | -15.0% | -2.1% | 39.0% | |
Competitors are the stored peer set for CRDL.TO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 78.76K | 0 | 0 | 0 | 0 |
| Cost of Revenue | 220.42K | 219.91K | 248.36K | 373.11K | 101.98K |
| Gross Profit | 78.76K | (219.91K) | (248.36K) | (373.11K) | (101.98K) |
| Gross Margin | 100.0% | — | — | — | — |
| Research & Development | 10.87M | 18.96M | 14.22M | 14.01M | 14.02M |
| Selling, General & Admin | 27.87M | 22.37M | 15.56M | 25.89M | 20.2M |
| Operating Expenses | 38.74M | 41.34M | 29.54M | 39.9M | 34.32M |
| Depreciation & Amortization | 220.42K | 219.91K | 248.36K | 373.11K | 101.98K |
| EBITDA | (38.44M) | (30.71M) | (27.88M) | (36.3M) | (34.21M) |
| EBITDA Margin | -48812.1% | — | — | — | — |
| Operating Income | (45.47M) | (50.34M) | (29.79M) | (40.28M) | (34.32M) |
| Operating Margin | -57736.3% | — | — | — | — |
| Interest Income | 106K | 1.24M | 2.04M | 1.19M | 726.4K |
| Interest Expense | 0 | 0 | 0 | 0 | 0 |
| Other Income / Expenses | 7.03M | 10.41M | 1.66M | 3.6M | 497.42K |
| Income Before Tax | (31.64M) | (30.93M) | (28.13M) | (36.68M) | (33.82M) |
| Pre-Tax Margin | -40170.4% | — | — | — | — |
| Income Tax Expense | (6.91M) | (19.41M) | 0 | 0 | 0 |
| Net Income | (24.72M) | (11.52M) | (28.13M) | (36.68M) | (33.82M) |
| Net Margin | -31391.5% | — | — | — | — |
| EPS (Basic) | (0.57) | (0.18) | (0.44) | (0.51) | (0.39) |
| EPS (Diluted) | (0.57) | (0.18) | (0.44) | (0.51) | (0.39) |
| Weighted Avg Shares | 43.22M | 62.51M | 64.46M | 71.57M | 86.99M |
| Weighted Avg Shares (Diluted) | 43.22M | 62.51M | 64.46M | 71.57M | 86.99M |
Cardiol Therapeutics Inc.
TSX:CRDL.TO
Intrinsic Alpha fair value
Locked
Current Price
$1.36
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.